CARLSMED, INC.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

CARL$14.52-5.2%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

(in thousands, except for share amounts)

Series A ConvertiblePreferred Stock · Series B ConvertiblePreferred Stock · Series C ConvertiblePreferred Stock · Common Stock · Additional · Accumulated Other · Total
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Paid-InCapital	AccumulatedDeficit	Comprehensive Loss	Stockholders’Equity (Deficit)
Balance as of December 31, 2024	4,902,814	$13,578	4,335,051	$29,801	4,890,123	$52,847	4,139,219	$—	$541	$(71,171)	$—	$(70,630)
Issuance of Series C convertible preferred stock, net of issuance costs of $80	—	—	—	—	1,117,743	12,503	—	—	—	—	—	—
Deemed dividend related to issuance of Series C convertible preferred stock	—	—	—	—	—	—	—	—	(584)	—	—	(584)
Vesting of early exercised stock options	—	—	—	—	—	—	8,960	—	10	—	—	10
Exercise of vested stock options	—	—	—	—	—	—	422,364	—	149	—	—	149
Stock-based compensation expense	—	—	—	—	—	—	—	—	175	—	—	175
Net loss	—	—	—	—	—	—	—	—	—	(5,729)	—	(5,729)
Balance as of March 31, 2025	4,902,814	$13,578	4,335,051	$29,801	6,007,866	$65,350	4,570,543	$—	$291	$(76,900)	$—	$(76,609)
Vesting of early exercised stock options	—	—	—	—	—	—	8,960	—	10	—	—	10
Exercise of vested stock options	—	—	—	—	—	—	24,253	—	34	—	—	34
Stock-based compensation expense	—	—	—	—	—	—	—	—	258	—	—	258
Net loss	—	—	—	—	—	—	—	—	—	(6,766)	—	(6,766)
Balance as of June 30, 2025	4,902,814	$13,578	4,335,051	$29,801	6,007,866	$65,350	4,603,756	$—	$593	$(83,666)	$—	$(83,073)
Balance as of December 31, 2025	—	$—	—	$—	—	$—	26,604,505	$—	$199,674	$(100,805)	$—	$98,869
Vesting of early exercised stock options	—	—	—	—	—	—	8,961	—	10	—	—	10
Cashless exercise of warrants	—	—	—	—	—	—	30,366	—	—	—	—	—
Exercise of vested stock options	—	—	—	—	—	—	537,669	—	436	—	—	436
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,629	—	—	1,629
Net loss	—	—	—	—	—	—	—	—	—	(8,696)	—	(8,696)
Balance as of March 31, 2026	—	$—	—	$—	—	$—	27,181,501	$—	$201,749	$(109,501)	$—	$92,248
Vesting of early exercised stock options	—	—	—	—	—	—	8,961	—	11	—	—	11
Exercise of vested stock options	—	—	—	—	—	—	10,019	—	36	—	—	36
Issuance of common stock in connection with the employee stock purchase plan	—	—	—	—	—	—	25,278	—	207	—	—	207
Stock-based compensation expense	—	—	—	—	—	—	—	—	2,271	—	—	2,271
Other comprehensive loss	—	—	—	—	—	—	—	—	—	—	(17)	(17)
Net loss	—	—	—	—	—	—	—	—	—	(10,510)	—	(10,510)
Balance as of June 30, 2026	—	$—	—	$—	—	$—	27,225,759	$—	$204,274	$(120,011)	$(17)	$84,246

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.